LA JOLLA, Calif. , July 8, 2025 /PRNewswire/ -- CalciMedica Inc . ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny , Ph.D., Chief Executive Officer, will participate in a fireside chat at... Read More